Grant: Discovery Grants Program - Individual
University of Western Ontario
$30,000.00
Regulation of cellular growth in hypoxia
FY 2015-16
Summary
OBJECTIVE: To determine the key molecular interactions that regulate insulin-like growth factor-I (IGF-I)-mediated cell growth in hypoxia. My long term goal is to elucidate the basic mechanisms that regulate growth at the cellular level.
BACKGROUND: Growth of most metazoans is inherently tied to the availability of O2 such that mechanisms have evolved to survive severe hypoxia. The mechanistic target of rapamycin (mTOR) integrates signals from O2 to positively regulate cell growth. mTOR functions through two complexes: mTORC1/C2. IGF-I increases cell growth. IGFBP-1 inhibits IGF actions. Phosphorylation of IGFBP-1 inhibits IGF-I's growth promoting actions. Protein kinase CK2 regulates cell growth by modulating many pathways and can phosphorylate IGFBP-1. Hypoxia inhibits mTORC1 and stimulates IGFBP-1 phosphorylation. The role of mTOR and CK2 in regulation of IGF-I function is unknown.
HYPOTHESIS: Based on previous and preliminary data, my overall hypothesis is that mTOR inhibition and CK2 activation are required for hypoxia-induced hyperphosphorylation of IGFBP-1.
I will test this in three specific aims:
Aim 1: Experimentally establish if mTORC1 regulates IGF-I-stimulated cellular growth.
I hypothesize that mTORC1 inhibition induces IGFBP-1 phosphorylation in hypoxia. I will use RNAi to inhibit/activate mTORC1/C2 with/without hypoxia. I will determine phosphorylation of mTOR effectors, IGFBP-1 phosphorylation, cell growth, IGF-I function using immunobloting and mass spectrometry to identify mTORC1 as a regulator of IGFBP-1 phosphorylation.
Aim 2: Identify the mechanism by which mTOR regulates IGF-I actions.
Studies from my laboratory have demonstrated that mTOR inhibition decreases IGF-I function, an effect that is prevented by inhibition of CK2. I hypothesize that CK2 directly phosphorylates IGFBP-1. I will test whether IGFBP-1 is a bona fide substrate for CK2 using e.g. (i) CK2 inhibitor-resistant mutants (ii) in vitro mutagenesis and (v) Co-IP to show CK2 directly interacts with IGFBP-1.
Aim 3:Explore the mechanistic link between mTOR, IGF-I and CK2 in modulation of cell growth in hypoxia
I hypothesize that mTORC1 inhibition activates CK2 in hypoxia resulting in increased phosphorylation of specific IGFBP-1 sites, which inhibit IGF-I actions. I will study the effects of mTOR silencing/activation on IGFBP-1 phosphorylation in cells with CK2 siRNA; and CK2 activity and IGFBP-1 phosphorylation in response to mTOR siRNA/activation.
SIGNIFICANCE: My work will contribute to fundamental understanding of the evolutionary conserved mechanisms involved in cell growth during hypoxia.
HQP: Trainees in my laboratory will receive a strong background in the fundamentals of protein biochemistry, functional-proteomics, and molecular-cell biology to achieve recognition/scholarships and continue with a career in academia/industry/governmental laboratories.
Program
Discovery Grants Program - Individual
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
RGPIN-2015-05000
Name nom
Gupta, Madhulika
Department département
Biochemistry - Biochemistry
Organization id
36
Institution établissement
University of Western Ontario
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
30000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1200
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Advancement of knowledge
Area of application fr
Avancement des connaissances
Research subject code
5403
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Proteins and peptides, amino acids
Research subject fr
Protéines et peptides, acides aminés
Partie
1
Nb partie
1
Application title
Regulation of cellular growth in hypoxia
Keyword
NSERC
Application summary
<p><strong>OBJECTIVE</strong>: To determine the key molecular interactions that regulate insulin-like growth factor-I (IGF-I)-mediated cell growth in hypoxia. My long term goal is to elucidate the basic mechanisms that regulate growth at the cellular level.
<br />
<br />
<strong>BACKGROUND:</strong> Growth of most metazoans is inherently tied to the availability of O<sub>2</sub> such that mechanisms have evolved to survive severe hypoxia. The mechanistic target of rapamycin (mTOR) integrates signals from O<sub>2</sub> to positively regulate cell growth. mTOR functions through two complexes: mTORC1/C2. IGF-I increases cell growth. IGFBP-1 inhibits IGF actions. Phosphorylation of IGFBP-1 inhibits IGF-I's growth promoting actions. Protein kinase CK2 regulates cell growth by modulating many pathways and can phosphorylate IGFBP-1. Hypoxia inhibits mTORC1 and stimulates IGFBP-1 phosphorylation. The role of mTOR and CK2 in regulation of IGF-I function is unknown.
<br />
<br />
<strong>HYPOTHESIS</strong>: Based on previous and preliminary data, my overall hypothesis is that mTOR inhibition and CK2 activation are required for hypoxia-induced hyperphosphorylation of IGFBP-1. </p>
<p>I will test this in three specific aims:
<br />
<br />
<strong>Aim 1</strong>: <em>Experimentally establish if mTORC1 regulates IGF-I-stimulated cellular growth</em>.
<br />
I hypothesize that mTORC1 inhibition induces IGFBP-1 phosphorylation in hypoxia. I will use RNAi to inhibit/activate mTORC1/C2 with/without hypoxia. I will determine phosphorylation of mTOR effectors, IGFBP-1 phosphorylation, cell growth, IGF-I function using immunobloting and mass spectrometry to identify mTORC1 as a regulator of IGFBP-1 phosphorylation.
<br />
<br />
<strong>Aim 2</strong>: <em>Identify the mechanism by which mTOR regulates IGF-I actions</em>.
<br />
Studies from my laboratory have demonstrated that mTOR inhibition decreases IGF-I function, an effect that is prevented by inhibition of CK2. I hypothesize that CK2 directly phosphorylates IGFBP-1. I will test whether IGFBP-1 is a bona fide substrate for CK2 using e.g. (i) CK2 inhibitor-resistant mutants (ii) in vitro mutagenesis and (v) Co-IP to show CK2 directly interacts with IGFBP-1.
<br />
<br />
<strong>Aim 3:</strong><em>Explore the mechanistic link between mTOR, IGF-I and CK2 in modulation of cell growth in hypoxia</em><br />
I hypothesize that mTORC1 inhibition activates CK2 in hypoxia resulting in increased phosphorylation of specific IGFBP-1 sites, which inhibit IGF-I actions. I will study the effects of mTOR silencing/activation on IGFBP-1 phosphorylation in cells with CK2 siRNA; and CK2 activity and IGFBP-1 phosphorylation in response to mTOR siRNA/activation.
<br />
<br />
<strong>SIGNIFICANCE</strong>: My work will contribute to fundamental understanding of the evolutionary conserved mechanisms involved in cell growth during hypoxia.
<br />
<strong><br />
HQP:</strong> Trainees in my laboratory will receive a strong background in the fundamentals of protein biochemistry, functional-proteomics, and molecular-cell biology to achieve recognition/scholarships and continue with a career in academia/industry/governmental laboratories.</p>